AU2021327733A1 - Annexin a1 n-terminal peptide formulations and methods - Google Patents

Annexin a1 n-terminal peptide formulations and methods Download PDF

Info

Publication number
AU2021327733A1
AU2021327733A1 AU2021327733A AU2021327733A AU2021327733A1 AU 2021327733 A1 AU2021327733 A1 AU 2021327733A1 AU 2021327733 A AU2021327733 A AU 2021327733A AU 2021327733 A AU2021327733 A AU 2021327733A AU 2021327733 A1 AU2021327733 A1 AU 2021327733A1
Authority
AU
Australia
Prior art keywords
pharmaceutical formulation
liquid pharmaceutical
solution
formulation according
annexin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021327733A
Other languages
English (en)
Other versions
AU2021327733A9 (en
Inventor
Jens Thostrup Bukrinski
Mette Hamborg Jensen
Pernille Sønderby TUELUNG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Resother Pharma AS
Original Assignee
Resother Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resother Pharma AS filed Critical Resother Pharma AS
Publication of AU2021327733A1 publication Critical patent/AU2021327733A1/en
Publication of AU2021327733A9 publication Critical patent/AU2021327733A9/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU2021327733A 2020-08-21 2021-08-20 Annexin a1 n-terminal peptide formulations and methods Pending AU2021327733A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20192142.6 2020-08-21
EP20192142 2020-08-21
PCT/EP2021/073186 WO2022038281A1 (en) 2020-08-21 2021-08-20 Annexin a1 n-terminal peptide formulations and methods

Publications (2)

Publication Number Publication Date
AU2021327733A1 true AU2021327733A1 (en) 2023-04-20
AU2021327733A9 AU2021327733A9 (en) 2023-04-27

Family

ID=72193322

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021327733A Pending AU2021327733A1 (en) 2020-08-21 2021-08-20 Annexin a1 n-terminal peptide formulations and methods

Country Status (10)

Country Link
US (2) US20240041977A1 (https=)
EP (3) EP4200320A1 (https=)
JP (1) JP2023539476A (https=)
CN (1) CN116323649A (https=)
AU (1) AU2021327733A1 (https=)
CA (1) CA3192030A1 (https=)
ES (1) ES3031633T3 (https=)
HU (1) HUE071875T2 (https=)
PL (1) PL4200319T3 (https=)
WO (2) WO2022038258A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3192030A1 (en) * 2020-08-21 2022-02-24 Resother Pharma A/S Annexin a1 n-terminal peptide formulations and methods
WO2024003338A1 (en) * 2022-06-30 2024-01-04 Resother Pharma A/S Annexin a1 liquid pharmaceutical composition
WO2024189056A1 (en) 2023-03-13 2024-09-19 Resother Pharma A/S Annexin a1 administration regime
WO2024189054A1 (en) 2023-03-13 2024-09-19 Resother Pharma A/S Annexin a1 delayed dosing
WO2025083393A1 (en) 2023-10-16 2025-04-24 Therakind Limited Antimicrobial use of peptides derived from annexin a1
WO2025083394A1 (en) 2023-10-16 2025-04-24 Therakind Limited Antimicrobial use of annexin a1 protein

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9283260B2 (en) * 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
AU2012271453B2 (en) * 2011-06-15 2017-07-06 Resother Pharma Aps Anti-inflammatory pharmaceutical products
JP6117219B2 (ja) * 2011-10-14 2017-04-19 バクスアルタ ゲーエムベーハー 陰イオン交換クロマトグラフィによるタンパク質の精製方法
EP3838285A1 (en) 2014-04-22 2021-06-23 TXP Pharma GmbH Peptide analogues with branched amino acid probe(s)
CN110302176A (zh) * 2019-06-25 2019-10-08 中国人民解放军陆军军医大学 一种抗炎多肽纳米药物及制备方法
CA3192030A1 (en) * 2020-08-21 2022-02-24 Resother Pharma A/S Annexin a1 n-terminal peptide formulations and methods
WO2024003338A1 (en) * 2022-06-30 2024-01-04 Resother Pharma A/S Annexin a1 liquid pharmaceutical composition

Also Published As

Publication number Publication date
US20240041977A1 (en) 2024-02-08
EP4595950A2 (en) 2025-08-06
US20230295255A1 (en) 2023-09-21
EP4200319B1 (en) 2025-04-16
WO2022038281A1 (en) 2022-02-24
PL4200319T3 (pl) 2025-08-18
AU2021327733A9 (en) 2023-04-27
JP2023539476A (ja) 2023-09-14
HUE071875T2 (hu) 2025-09-28
CA3192030A1 (en) 2022-02-24
EP4200319C0 (en) 2025-04-16
WO2022038258A1 (en) 2022-02-24
EP4200320A1 (en) 2023-06-28
EP4200319A1 (en) 2023-06-28
EP4595950A3 (en) 2025-10-29
CN116323649A (zh) 2023-06-23
ES3031633T3 (en) 2025-07-10

Similar Documents

Publication Publication Date Title
EP4200319B1 (en) Annexin a1 n-terminal peptide formulations and methods
AU2016335287A1 (en) Pharmaceutical formulations for the oral delivery of peptide drugs
CN102378635A (zh) 重组人白蛋白-人粒细胞集落刺激因子融合蛋白的新稳定制剂
EP4262745B1 (en) Pharmaceutical composition of glp-1/glp-2 dual agonists
AU2021399904B2 (en) Pharmaceutical composition of glp-1/glp-2 dual agonists
US20230405088A1 (en) Pharmaceutical Composition of GLP-1/GLP-2 Dual Agonists
CN115605218B (zh) 用于治疗大疱性表皮松解症的归巢肽引导的核心蛋白聚糖缀合物
CN116710474A (zh) 肽制剂及其眼科用途
RU2852511C1 (ru) Фармацевтическая композиция двойных агонистов glp-1/glp-2
TWI921427B (zh) Glp-1/glp-2雙重促效劑之醫藥組合物
RU2855486C1 (ru) Фармацевтическая композиция двойных агонистов glp-1/glp-2
RU2855506C1 (ru) Фармацевтическая композиция двойных агонистов glp-1/glp-2
JP2001522814A (ja) 増大されたｉｇｆ−ｉ溶解性を提供する組成物
US20230272024A1 (en) Fibroblast growth factor 7 peptide
HK40095698A (en) Pharmaceutical composition of glp-1/glp-2 dual agonists
HK40095698B (en) Pharmaceutical composition of glp-1/glp-2 dual agonists
EA045982B1 (ru) СТАБИЛЬНЫЙ ЛИОФИЛИЗИРОВАННЫЙ СОСТАВ НА ОСНОВЕ G-CSF, СЛИТОГО С ГИБРИДНЫМ Fc
KR20180122144A (ko) 인슐린 비강 전달용 제제

Legal Events

Date Code Title Description
SREP Specification republished